Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease [0.03%]
当前移植物抗宿主病预防和治疗的进展
Sameem Abedin,Mehdi Hamadani
Sameem Abedin
Purpose of review: Graft-versus-host disease (GVHD) is a serious complication after allogeneic HCT. Recently, several pivotal studies have been conducted demonstrating significant improvements in the management of GVHD. H...
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas [0.03%]
T细胞淋巴瘤自体造血干细胞移植后的维持治疗
Zachary Braunstein,Jonathan E Brammer
Zachary Braunstein
Purpose of review: Given the poor outcomes for peripheral T-cell lymphomas (PTCL), stem cell transplant (SCT) remains an important therapeutic approach. Post-SCT relapse is common and maintenance therapy post-SCT is incre...
K Thaw,C N Harrison,P Sriskandarajah
K Thaw
Purpose of review: The landscape of myelofibrosis (MF) has changed since the discovery of the JAK2 V617F mutation and subsequent development of JAK inhibitors (JAKis). However, treatment with JAKis remain a challenge. In ...
Akhil Rajendra,Vikas Gupta
Akhil Rajendra
Purpose of review: Allogeneic hematopoietic cell transplantation is the only potentially curative treatment for myelofibrosis. This review discusses issues not well-covered by existing guidelines: timing of transplant, pr...
Isabel Farmer,Deepti H Radia
Isabel Farmer
Purpose of review: Since identification of Systemic mastocytosis (SM) as a distinct disease entity by the World Health Organisation (WHO), there has been a wealth of new research in therapeutic targeting of the pathogenic...
Barbara Mora,Cristina Bucelli,Daniele Cattaneo et al.
Barbara Mora et al.
Purpose of review: Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). Median overall survival (OS) of pre-PMF, overt-PMF and SMF patients is around 14 years, seven and nine yea...
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma [0.03%]
靶向BCMA、GPRC5D和FcRH5的双特异性抗体在多发性骨髓瘤治疗中的毒性管理
Darren Pan,Joshua Richter
Darren Pan
Purpose of review: The introduction of bispecific antibodies is one of the most significant recent advances in the treatment of relapsed/refractory multiple myeloma. This review will summarize the management of the toxici...
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals [0.03%]
酪氨酸激酶抑制剂和生物制剂时代嗜酸性粒细胞增多症患者的诊疗思路
Johannes Lübke,Georgia Metzgeroth,Andreas Reiter et al.
Johannes Lübke et al.
Purpose of review: In this review, we aim to explore the optimal approach to patients presenting with eosinophilia, considering recent advances in diagnostic and therapeutic strategies. Specifically, we focus on the integ...
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia [0.03%]
治疗复发及难治性瓦尔登斯特伦巨球蛋白血症患者的新型策略
Karan L Chohan,Prashant Kapoor
Karan L Chohan
Purpose of review: Waldenström macroglobulinemia is a rare non-Hodgkin lymphoma (NHL) characterized by lymphoplasmacytic bone marrow infiltration associated with an immunoglobulin M (IgM) monoclonal gammopathy. Over the ...
MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications [0.03%]
费城染色体阳性急性淋巴细胞白血病的微小残留病：方法学与临床意义
Valerie Tran,Kiarash Salafian,Kenan Michaels et al.
Valerie Tran et al.
Purpose of review: Measurable residual disease (MRD) is integral in the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This review discusses the current methods used to evaluate M...